trending Market Intelligence /marketintelligence/en/news-insights/trending/boiqhbvees0kbeqhxrplgw2 content esgSubNav
In This List

ObsEva infertility treatment succeeds in phase 3 study

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


ObsEva infertility treatment succeeds in phase 3 study

Swiss biopharmaceutical company ObsEva SA said the phase 3 study of nolasiban in infertile women met its main goal.

Results from the Implant2 trial showed nolasiban improved the pregnancy rate of infertile women at 10 weeks.

Nolasiban is being developed for improving pregnancy rate following in vitro fertilization/intracytoplasmic sperm injection procedures, which are meant to treat infertility.

Nolasiban was well-tolerated, with low rates of treatment discontinuation and four recorded serious side effects, none of which were reported to be related to treatment.

Infertility affects about 10% of reproductive-aged couples, with annual assisted reproduction technology cycles approximating 1.6 million worldwide, ObsEva said in a statement.

ObsEva intends to seek feedback from U.S. and European regulatory authorities based upon the trial data to determine a path forward for the drug.